You are here: Industry Insights > Heart failure

News List

Follow-Up Within Seven Days of Heart Failure Discharge Beneficial drugs
December 18, 2018
For patients with heart failure, follow-up care within seven days of discharge from the emergency department is associated with lower rates of long-term mortality and subsequent admissions.....
"Biomarkers can play a key role in improving diagnosis and disease management of heart failure. " biospectrumasia
November 15, 2018
Recently, Priyanka Bajpai from BioSpectrum Asia spoke to Dr Antoni Bayes-Genis on the need to staying healthy and the future of NT-proBNP as a cardiac biomarker.
AstraZeneca sells European rights for heart failure treatment for $210M biospectrumasia
July 25, 2018
Cheplapharm would pay AstraZeneca $200m on completion of the agreement, expected to be finalised in the third quarter of 2018, plus a time-bound payment of $10m and sales-contingent milestones.
AstraZeneca sells Atacand rights to Cheplapharm pharmatimes
July 25, 2018
AstraZeneca is selling rights to its heart failure and hypertension brand Atacand in Europe, in a move that it says will expand its commercial potential in 28 countries.
Orion takes repurposed heart failure drug into phase 3 for ALS fiercebiotech
July 09, 2018
Finnish drugmaker Orion Pharma is pressing ahead with a pivotal trial for its amyotrophic lateral sclerosis drug ODM-109, despite mixed results in a phase 2 trial.
Bayer expands Broad Institute partnership to focus on heart failure pharmafile
July 06, 2018
The PCL will be situated at the Massachusetts-based biomedical and genomic research centre. The cardiology lab will leverage new tools and approaches in an effort to gain greater insight into the causes of heart failure while working towards developing me
Phase III CardiAMP Heart Failure Trial Featured in American Heart Journal biospace
April 10, 2018
BioCardia®, Inc., [OTC: BCDA] a leader in cardiovascular regenerative medicine, today announced the publication of the Phase III CardiAMP Heart Failure Trial design paper in the American Heart Journal.
Aspirin lowers risk of death for patients with diabetes and heart failure europeanpharmaceuticalreview
March 01, 2018
Researchers assess aspirin as a preventive measure for patients who have both diabetes and heart failure…
New Novartis Entresto® real world evidence data shows beneficial impact on quality of life in people worldpharmanews
November 14, 2017
Novartis has announced new results from a real-world database study of patients in Germany prescribed Entresto® (sacubitril/valsartan) for heart failure with reduced ejection fraction (HFrEF).
After a slow start, Novartis finally gains market traction with heart drug Entresto fiercepharma
August 16, 2017
Novartis CEO Joe Jimenez told investors during a recent earnings call that heart failure drug Entresto is winning over insurers.

Previous page 1 2 3 4 5 6 7 Next page